Papapetropoulos Spyros 4/A
4/A · Neuphoria Therapeutics Inc. · Filed May 19, 2025
Insider Transaction Report
Form 4/AAmended
Papapetropoulos Spyros
DirectorPresident and CEO
Transactions
- Award
Employee Stock Option (Right-to-Buy)
2025-04-16$5.16/sh+27,000$139,320→ 39,529 totalExercise: $5.16Exp: 2035-04-16→ Common Stock (27,000 underlying)
Footnotes (2)
- [F1]The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares.
- [F2]Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.